Compare SAIA & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SAIA | NBIX |
|---|---|---|
| Founded | 1924 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trucking Freight/Courier Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.2B | 13.2B |
| IPO Year | 2002 | 1996 |
| Metric | SAIA | NBIX |
|---|---|---|
| Price | $359.97 | $162.00 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 19 | 22 |
| Target Price | ★ $391.06 | $180.91 |
| AVG Volume (30 Days) | 487.9K | ★ 1.3M |
| Earning Date | 04-30-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 41.95 |
| EPS | ★ 5.37 | 3.30 |
| Revenue | ★ $3,234,286,000.00 | $161,626,000.00 |
| Revenue This Year | $7.29 | $24.73 |
| Revenue Next Year | $9.08 | $13.14 |
| P/E Ratio | $69.71 | ★ $50.32 |
| Revenue Growth | 0.79 | ★ 977.51 |
| 52 Week Low | $249.32 | $122.14 |
| 52 Week High | $494.71 | $186.12 |
| Indicator | SAIA | NBIX |
|---|---|---|
| Relative Strength Index (RSI) | 33.15 | 40.24 |
| Support Level | $357.64 | $153.96 |
| Resistance Level | $376.30 | $169.57 |
| Average True Range (ATR) | 16.81 | 6.37 |
| MACD | -5.69 | -2.08 |
| Stochastic Oscillator | 20.99 | 0.64 |
Saia ranks among the 10 largest less-than-truckload carriers in the United States, with more than 210 facilities and a fleet of more than 7,500 tractors and 26,000 trailers. As a national LTL carrier, the firm offers time-definite and expedited options for shipments ranging between 100 and 10,000 pounds. Saia ranks among the top-tier providers in terms of profitability.
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.